Targeting IgE is generally beneficial in disease treatment24; in asthma, omalizumab treatment can reduce exacerbation rates,24, 25 while in IgE‐mediated allergies omalizumab and a second anti‐IgE antibody, ligelizumab, both reduce serum IgE amounts and show promise as adjuncts to immunotherapy26, 27; anti‐IgE treatment in the context of immunotherapy with allergen supports increases in allergen‐specific IgG4 production28 and increases the maximum tolerated dose in an oral food challenge.29 Here, IGHE is linked to allergic disease.